secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126671
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies FY2025 net loss $147M; cash runway into Q2 2027; BLA on track H1 2026
--------------------------------------------------------------------------------

- Net loss of $147M for FY2025, compared to $113.9M in FY2024; diluted EPS -$1.05.
- Operating income $5.6M, up from $4.2M; R&D expenses rose to $116.7M due to pre-commercial inventory and clinical costs.
- Cash and equivalents $194.2M as of Dec 31, 2025; additional $94M received Jan 2026; funding into Q2 2027.
- BLA submission for VIASKIN Peanut Patch in children aged 4-7 years anticipated H1 2026; for toddlers 1-3 years H2 2026.
- Appointed Kevin Trapp as CCO and James Briggs as CHRO; Philina Lee nominated to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526126671/0001193125-26-126671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526126671/d113165d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer